In the IMmotion 010 study presented by Dr. Axel Bex, atezolizumab (anti-PD-L1) monotherapy was studied as adjuvant therapy in patients with #RCC and high risk of recurrence after resection. Results from this phase III trial did not prove that #Atezolizumab improved clinical outcomes vs pbo in the ITT population. Median DFS was 57.2 mo for atezo and 49.5 mo for placebo (HR: 0.93; P=0.495).
.png)